Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Gradalis, Sanofi, Monsanto, and More

Premium

Title: Construction of Bifunctional Short Hairpin RNA

Patent Number: 8,758,998

Filed: Feb. 1, 2012

Inventor: Donald Rao, Gradalis


Title: Host Cell Kinases as Targets for Antiviral Therapies against HCV Infection

Patent Number: 8,759,010

Filed: Sept. 8, 2009

Lead Inventor: Thomas Baumert, INSERM


Title: Short RNA Producing Gene Silencing in Cells

Patent Number: 8,759,102

Filed: Dec. 17, 2004

Lead Inventor: David Baulcombe, University of Cambridge (Plant Bioscience Limited)


Title: RNAi for the Control of Insects and Arachnids

Patent Number: 8,759,306

Filed: May 31, 2006

Inventor: Titus Jan Kaletta, Devgen (Syngenta)


Title: RNAi Probes Targeting Cancer-related Proteins

Patent Number: 8,759,308

Filed: July 28, 2010

Lead Inventor: Martin Gleave, University of British Columbia (OncoGenex)


Title: Use of siRNA Targeting SIPA1L1 for the Reduction of Adipogenesis

Patent Number: 8,759,311

Filed: Oct. 1, 2010

Lead Inventor: Diana Hall, Sanofi


Title: Methods and Compositions for Reducing Viral Genome Amounts in a Target Cell

Patent Number: 8,759,312

Filed: June 21, 2012

Lead Inventor: Peter Sarnow, Stanford University (Regulus Therapeutics)


Title: Treatment of Fibrosis using microRNA-19b

Patent Number: 8,759,313

Filed: Aug. 3, 2012

Lead Inventor: Laura Schrum, Charlotte-Mecklenburg Hospital


Title: Modulation of Exon Recognition in Pre-mRNA by Interfering RNA Structure

Patent Number: 8,759,507

Filed: Dec. 22, 2010

Inventor: Judith Van Deutekom, Leiden University Medical Center


Title: Methods for Genetic Control of Insect Infestation in Plants and Compositions Thereof

Patent Number: 8,759,611

Filed: Dec. 20, 2010

Lead Inventor: James Baum, Monsanto

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.